| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |